Objective Outcome misclassification may occur in observational studies using administrative databases. We evaluated a two-step multiple imputation approach based on complementary internal validation data obtained from two subsamples of study participants to reduce bias in hazard ratio (HR) estimates in Cox regressions. Methods We illustrated this approach using data from a surveyed sample of 6247 individuals in a study of statin-diabetes association in Quebec. We corrected diabetes status and onset assessed from health administrative data against self-reported diabetes and/or elevated fasting blood glucose (FBG) assessed in subsamples. The association between statin use and new onset diabetes was evaluated using administrative data and the corrected data. By simulation, we assessed the performance of this method varying the true HR, sensitivity, specificity, and the size of validation subsamples. Results The adjusted HR of new onset diabetes among statin users versus non-users was 1.61 (95% confidence interval: 1.09-2.38) using administrative data only, 1.49 (0.95-2.34) when diabetes status and onset were corrected based on self-report and undiagnosed diabetes (FBG ≥ 7 mmol/L), and 1.36 (0.92-2.01) when corrected for self-report and undiagnosed diabetes/impaired FBG (≥ 6 mmol/L). In simulations, the multiple imputation approach yielded less biased HR estimates and appropriate coverage for both non-differential and differential misclassification. Large variations in the corrected HR estimates were observed using validation subsamples with low participation proportion. The bias correction was sometimes outweighed by the uncertainty introduced by the unknown time of event occurrence. Conclusion Multiple imputation is useful to correct for outcome misclassification in time-to-event analyses if complementary validation data are available from subsamples.
INTRODUCTION
Health services administrative databases are frequently used to assess drug effectiveness and safety. 1 Exposure and outcome misclassification in these databases may compromise results validity. [2] [3] [4] [5] [6] A systematic review of a diabetes case definition from administrative databases reported sensitivities between 74.4% and 92.3% and specificities between 96.9% and 99.6%. 5 Misclassification in diabetes status may partly explain the discrepancy in observational study results that assessed the association between statin use and new onset diabetes. [7] [8] [9] [10] Various methods have been developed to account for potential exposure and outcome misclassifications in the analyses of observational data. [11] [12] [13] [14] [15] [16] Validation studies based on subsamples have been suggested. Misclassification is treated as a missing data problem, and multiple imputation (MI) 17, 18 is used with the gold standard observed for participants in the validation subsample but missing for all others. Simulation studies have shown that this method corrects hazard ratio (HR) estimates for exposure misclassification 19 and removes outcome misclassification bias from odds ratios in logistic regressions. 20 This method's performance depends on factors such as the degree of misclassification, the size of the primary and validation samples, and the main analytic question of interest. 21, 22 However, the performance of MI in correcting for outcome misclassification in time-toevent analyses based on administrative databases has not been examined. In these analyses, inaccurate information may occur in the outcome status and its time of occurrence, and the performance of MI cannot be directly inferred from the results of logistic regression models.
Validation data to correct for outcome misclassification may be obtained from various sources such as a subsample survey, chart review, or clinical examinations. [23] [24] [25] [26] [27] While error-free data may not be available from a single validation source in practice, combining information from more than one source may be necessary to reduce the misclassification error.
We examined a two-step MI approach combining information from two sources of internal validation data to account for outcome misclassification in Cox regression in a health administrative database study 28 and assessed the performance of this approach by simulation.
METHODS

Primary study
Demographic, physician and pharmacy claims, and hospitalization data from January 1997 to December 2010 were obtained on a stratified random sample of 6247 individuals 20 years of age or older (the primary sample) from the Quebec Public Health Insurance Agency, Régie de l'assurance maladie du Québec (RAMQ). The database and study sample were described elsewhere. 28 Permission to link the data and to conduct the current study was obtained from the Provincial Ethics Board, Commission d'accès à l'information.
Individuals covered by the provincial drug plan were eligible for the study. Those who filled a prescription for statin in the study period (statin users) were identified at the date of the first prescription (index date). Statin users who had neither a diabetes diagnosis (at least one physician billing or one hospitalization for diabetes) within the 2-year period before the index date nor an antidiabetic medication in the year before the index date were 1-3 individually matched to non-users by age (±2 years) and sex. A non-user was an individual who did not use statin at any time from 1 year prior to the index date of his or her matched user to 90 days after. We excluded individuals who died within 90 days after the index date. Diabetes onset (main outcome) was defined as the earliest date of a physician claim or hospital admission for diabetes, or filled prescription for an antidiabetic drug. Subjects were followed from index date until diabetes onset, death, the end of the study period, or statin initiation for non-users, whichever came first.
A Cox proportional hazards (PH) model stratified by the matched sets was used to estimate the HR of new onset diabetes among statin users versus non-users. The model adjusted for potential confounders available from RAMQ including age, sex, all-cause hospitalization, hypertension, ischemic heart disease, heart failure and cancer identified in the past year, and a social deprivation index. [29] [30] [31] [32] The censoring events (death and statin initiation) were examined in additional analyses for possible competing risks (Appendix S1).
Validation study
Self-reported diabetes (SRdiabetes) data were collected from a telephone survey that we conducted with the assistance of the Institut de la Statistique du Quebec. All individuals in the primary sample were contacted between March and July 2009 and reported on physician-diagnosed diabetes and age at diagnosis. They were asked to provide a self-collected fasting capillary blood sample for glucose measurement using the materials provided by the Institut de la Statistique du Quebec via mail. 28 The validation study yielded two subsamples: 3322 survey participants and 1599 survey participants who also provided analyzable blood samples. The validation and administrative data were linked by a unique patient identifier. We assumed that the survey and blood tests were conducted on the first day of the survey period for all participants; the validation information for non-participants was missing at random; and the predictive values were transportable between the validation samples and the primary sample.
Correction for outcome misclassification
In the administrative data, three types of outcome misclassifications were considered: (i) diabetes is present but has not been diagnosed and was not recorded in the database (undiagnosed and unknown to the patient); (ii) diabetes is present and has been diagnosed but was not recorded in the database; and (iii) the individual is non-diabetic but has been classified as diabetic in the database (Figure 1) . We assumed that patients accurately reported the true diabetes status, which is known to them; therefore, only the undiagnosed diabetes error was assumed in the self-report data; fasting blood glucose (FBG) results were used to correct for the undiagnosed diabetes in these data.
Subjects with elevated FBG levels were identified using two thresholds: ≥7 mmol/L for diabetes and 6.1-6.9 mmol/L for impaired fasting glucose (IFG). 33 The two-step MI method was applied by first modeling elevated FBG (yes/no) on SRdiabetes and patient characteristics (Table 1) to impute the indicator values of elevated FBG for survey participants who did not provide blood samples. Five imputations were performed using monotone logistic regression method. 34 For participants who reported no diabetes but had elevated FBG (IFG or undiagnosed diabetes), their diabetes/IFG onset date was set at the blood test date. Although the true diabetes onset was certainly prior to the test date, our assumption mimics a real-life study where the true onset date is set at the first positive test date. Positive SRdiabetes status was not modified considering that in real-life studies, those who self-report diabetes may not be invited to a blood test because their treatment may affect test results. Diabetes onset time was assumed to be error free when diabetes status was correctly classified among survey participants.
In the second step, SRdiabetes corrected for elevated FBG was used as a presumed gold standard to correct for misclassification in diabetes status in the primary sample. For survey participants, the corrected SRdiabetes status was modeled on diabetes status assessed from administrative data, exposure status, and patient characteristics to impute missing gold-standard values for survey non-participants using monotone logistic regression methods. Five imputations were performed for each imputed dataset from the previous step, creating a total of 25 copies of complete datasets in the two steps. RAMQ-based diabetes onset time was assumed correct if diabetes status was not misclassified. Onset time for false positive cases was corrected to the censoring time. For false negative cases among survey participants, diabetes onset date was changed to the date derived from the self-reported age at diabetes diagnosis. This date was imputed using the propensity score method 35 for survey non-participants (details in Appendix S2).
Matching and data analyses were then repeated as in the primary study for each of the 25 complete datasets, and the results were combined using the SAS MIANALYZE procedure. 36 Figure 1. Information on diabetes status available in the primary sample and validation subsamples. Three types of errors were assumed in the administrative data; one type of error (undiagnosed diabetes) was assumed in the self-report data
Simulation
We simulated data to reproduce the diabetes and exposure situation of our random sample described previously. In each simulation, our primary sample consisted of 10 000 individuals with their exposure status, observed and true outcome status, and time of onset (Appendix S3). [37] [38] [39] Participants were randomly selected into the two validation subsamples for survey and blood test.
The true HR was compared with estimates from the naïve analyses of the observed outcome, the analysis of the corrected outcome based on the MI method, and a complete data analysis when validation data were available for the whole primary sample. We used the bias, 95% confidence interval (CI) coverage 40 and mean-squared error (MSE) 41 of the ln(HR) estimates to assess the performance of the proposed approach under several simulation scenarios varying the true HR, sensitivity, specificity, and the size of validation subsamples under both non-differential and differential misclassification. One set of scenarios explored the performance of the correction scheme in terms of the true HR and sensitivity at a 30% survey participation proportion. This proportion was chosen because it was close to the lowest response rate reported in nationwide health surveys. [42] [43] [44] [45] Another set of scenarios was to assess the MI method with respect to survey participation proportion for non-differential and differential misclassification. In the later, we focused on differential participation proportion below 30% across exposure groups. Specificity was 0.9 in all scenarios. The proportion of the blood test subsample in all scenarios was fixed at 50% of survey participants, which was similar to the participation proportion in biomedical assessments reported in other studies. 42, 43 In each scenario, the results were summarized over 10 000 simulations.
The simulations and analyses in this study were performed with the SAS 9.3 statistical software (SAS Institute Inc., Cary, USA).
RESULTS
The association between statin use and diabetes onset-the database study
In the primary sample, mean age was 49.7 years (standard deviation 16.4 years), and about half were men. The proportion of RAMQ-based diabetes cases was 10.6% (95%CI: 9.8-11.4%) in the primary sample, 11.8% (10.7-12.9%) among survey participants, and 14.3% (12.6-16.1%) among those who provided blood samples. Glucose test and survey participants were comparable with the primary sample on other characteristics ( Table 1) .
The proportion of SRdiabetes was 11.3% (95%CI: 9.8-12.9%) among glucose test participants (Table 2) . Adding those with elevated FBG to those with Table 2 ). Using self-reported and glucose test-derived diabetes as the reference standard and assuming differential misclassification, the MI method yielded an estimate of 14.7% (13.8-15.6%) for diabetes in the primary sample (Table 4) . When IFG was also incorporated into the reference standard, the estimated proportion of diabetes/IFG was 29.0% (27.9-30.1%).
The matched cohort included 1612 individuals, 403 of whom were statin users and 1209 were matched non-users. Mean age was 63.9 years (standard deviation 11.3 years). A larger proportion of statin users had previous all-cause hospitalization, ischemic heart disease, or used anti-hypertensive drugs in the past year (Table 3) . During 7720 person-years of follow-up, there were 148 new cases of RAMQ-based diabetes. The crude rate of new onset diabetes was 28.9 per 1000 person-years among statin users and 15.6 among non-users. In Cox PH models, the adjusted risk of new onset diabetes was higher among statin users compared with non-users (HR = 1.61; 95%CI: 1.09-2.38). Correcting for self-reported and glucose test-derived diabetes combined, the crude rate of new onset diabetes increased to 39.5 and 24.2 per 1000 person-years among users and non-users, respectively. The HR of statin users versus non-users 
Simulation results
The MI method markedly reduced bias because of outcome misclassification in HR estimates for every scenario examined in the simulations (Table 5) . Naïve ln(HR) estimates were biased for both non-differential and differential misclassification, with bias (À0.41 to 0.22 and À0.19 to 0.32, respectively) varying with the true HR and sensitivity. The MI method yielded estimates with less bias (À0.09 to 0.05) than the naïve analysis in all combinations of true HRs and degrees of misclassification explored. In the analysis of the complete data without missing validation information, slight underestimates were observed in all scenarios explored because of the unknown diabetes onset date for the undiagnosed cases identified through blood test. The MI method yielded results similar to those obtained in the complete data analysis.
Confidence intervals from the MI method maintained high coverage (95-96%) for all scenarios explored, while those from the naïve analyses showed poor coverage (4-66%) that varied with the true HR and sensitivity.
For a study sample of 10 000 subjects and the same validation proportions of 30% in both exposure groups, the bias-corrected ln(HR) estimates generally had equal or smaller MSEs than the naïve estimates when the naïve estimates suffered severe bias. In some scenarios, the reduction of bias by correction was offset by added imprecision. Table 6 presents results summarized from 10 000 samples with the same survey participation proportion of 10%, 20%, and 30% in both exposure groups, as well as different proportions of 20% in one group, 40% in the other, and vice versa. Results from the complete data analysis are also presented. For all examined combinations of validation proportion, the corrected ln(HR) estimates showed notable bias reduction and appropriate coverage (95-100%) under both non-differential and differential misclassification. RAMQ, Régie de l'assurance maladie du Québec; IFG, impaired fasting glucose; MI, multiple imputation; SD, standard deviation. *Data are n (%) unless otherwise stated. Covariates are relevant subject characteristics at the index date. † The number of subjects varied slightly in the 25 datasets created by the two-step MI method. Other data are the average of the 25 datasets; the counts had been rounded to the nearest integer. ‡ Time to diabetes onset among those who developed diabetes after the index date. § Any physician claim or hospitalization (primary or secondary diagnosis) in the past year.
With validation proportion of 10%, the correction method yielded estimates with larger variation (MSE 0.14 and 0.10 for the corrected estimates versus 0.11 and 0.04 for the naïve estimates under non-differential and differential misclassification, respectively). The MSE of the corrected ln(HR) estimates decreased as the validation proportion increased. With the same validation proportion ≥20% in both exposure groups, the corrected estimates based on the MI method (bias À0.07 to À0.06 for non-differential misclassification and À0.02 for differential misclassification) were similar to the estimates from the complete data analysis (bias À0.07 and À0.02 for non-differential and differential misclassification, respectively). HR, hazard ratio; ln(HR), natural log of the hazard ratio; MSE, mean-squared error. *For differential misclassification, sensitivity is presented as sensitivity for the exposed and sensitivity for the unexposed. † Bias is the difference between the average estimated ln hazard ratio and the true ln hazard ratio. ‡ Coverage is defined as the percentage of the simulations that the estimated 95% confidence interval included the true value. § MSE is the sum of squared bias and the variance of estimated ln hazard ratios. ¶
Complete data analysis was performed with 100% validation proportion in both validation subsamples. Blood test participation proportion was 50% in other scenarios. HR, hazard ratio; ln(HR), natural log of the hazard ratio; MSE, mean-squared error. *For differential misclassification, sensitivity is presented as sensitivity for the exposed and sensitivity for the unexposed. † Bias is the difference between the average estimated ln hazard ratio and the true ln hazard ratio. ‡ Coverage is defined as the percentage of the simulations that the estimated 95% confidence interval included the true value. § MSE is the sum of squared bias and the variance of estimated ln hazard ratios. ¶ Differential validation proportions in exposure groups are presented as validation proportion for the exposed and validation proportion for the unexposed. **Complete data analysis was performed with 100% validation proportion in both validation subsamples. Blood test participation proportion was 50% in other scenarios.
For differential participation across exposure groups, the MI method yielded estimates with less bias (À0.04 to À0.01) when the exposed group had higher validation proportion than the unexposed, compared with when the exposed group had lower validation proportion (bias À0.11 to À0.05). The resulting ln(HR) estimates from differential participation varied around the estimates from the complete data analysis.
DISCUSSION
Our simulation study considered various scenarios to address a real-world problem that is frequently encountered in pharmacoepidemiology. It showed an adequate performance of the MI method in correcting for outcome misclassification bias in HR estimates when internal validation subsamples of reasonable sizes are available. While validation data from a single source are not completely error free, a gold standard (or near gold standard) can be formed by combining information from complementary sources using MI. Inadequate sample size of the validation subsample creates complete or quasi-complete separation of outcome in the monotone logistic method of imputation. Alternative estimation methods such as Firth's penalized likelihood have been proposed to reduce the small sample bias and to produce finite and more consistent estimates. [46] [47] [48] The survey in our example had a 53.2% response rate, which was above the threshold (≥20%) found in our simulations. Moreover, 48.1% of surveyed individuals provided analyzable blood samples.
In our simulated validation study, we assumed that the information was missing at random (the probability of participation was independent of the participant's outcome given the observed outcome and covariates). In practice, the models should adjust for relevant observed covariates to avoid selection bias. 49 In our example, older individuals and those with diabetes were more inclined to participate in the survey and to return blood samples. While our MI method adjusted for these differences, residual confounding from unmeasured confounders and confounders that compromised the transportability assumption may have remained.
Studies have reported that the adjustment for misclassification of a binary outcome using logistic regression reduces the bias but may sometimes inflate the variability, yielding an estimator with a larger MSE compared with that obtained from an unadjusted method. 21 Similar findings were observed in our study.
The uncorrected estimates performed better than the corrected ones under poor validation proportions or when the uncorrected estimates were not severely biased. Nonetheless, the corrected HR estimates always acquired large gain in the CI coverage.
In our example, we found that a substantial proportion of diabetes cases identified from administrative data were misclassified compared with self-report and FBG measurements. Differential misclassification in diabetes among statin users and non-users was likely because of detection bias; statins are prescribed for subjects with abnormal cholesterol levels who may be routinely screened for diabetes.
Two or more physician billings and/or one or more hospitalizations for diabetes within a 2-year period are a frequently used algorithm to identify diabetes from administrative databases. 27, 50, 51 Our definition (≥1 physician claim and/or a hospitalization or an antidiabetic medication) had improved sensitivity but reduced specificity. 5, 27 However, the MI-based corrections rely on the correct specification of the gold-standard and observed outcome relationship and its transportability from the validation subsample to the whole study sample regardless of the outcome definition.
The true time of diabetes onset is unknown; thus, the proposed MI method cannot fully remove the bias. Assuming the same disease onset date for undiagnosed cases in both exposure groups may lead to a slight underestimation of the exposure-disease association. Nevertheless, the proposed method always yielded less biased estimates than the naïve analysis. Also, we assumed that the time of diagnosis was accurate if diabetes status was correctly classified. This may not be satisfied in practice because a delay in diagnosis is frequent in diabetes. 52 Different probability of diagnosis delay between exposure groups can cause bias towards either direction.
In our example, we used a single test of mailed-in fasting blood samples to identify IFG/undiagnosed diabetes. Results of this test may be prone to measurement errors. Confirming test results with a second glucose test before making a diagnosis is recommended. 53, 54 However, this was not feasible in our study. We also cannot exclude information and recall biases in our validation subsamples, which may have affected the corrected results.
Despite these potential limitations, our study demonstrated that MI is a useful procedure to correct the effect estimates in Cox PH models for outcome misclassification using data from validation subsamples.
